endpoint Clinical, the leader in global interactive response technology (IRT®) for clinical trials, and Berlinger & Co. AG, specializing in the production of innovative and customized solutions for monitoring temperature-sensitive goods in the pharmaceutical and medical industry, have announced their partnership to provide complete end to end visibility of the entire temperature history of an Investigational Medicinal Product (IMP).
| SAN FRANCISCO and SWITZERLAND, Oct. 6, 2021 /PRNewswire/ -- endpoint Clinical, the leader in global interactive response technology (IRT®) for clinical trials, and Berlinger & Co. AG, specializing in the production of innovative and customized solutions for monitoring temperature-sensitive goods in the pharmaceutical and medical industry, have announced their partnership to provide complete end to end visibility of the entire temperature history of an Investigational Medicinal Product (IMP).
“Over the last several years, the cold chain logistics market for clinical trials has shown a growth of about 10%. This is largely related to the increasing number of biologicals and monoclonal antibodies that are under study. Therefore, cold chain failure in clinical trials has an increasing impact,” says Dr. Harald van Weeren, Segment Manager Clinical Trials at Berlinger. Our organizations understand the risks of managing temperature-controlled IMP, and therefore, we focused on designing a solution to help reduce risk and eliminate the core issues. Such problems include limited transparency and missing information, the lack of immediate centralized visibility, time-consuming excursion management and slow decision making, time-consuming data consolidation for audits, wastage of drugs, and patient rescheduling or lost. Through this partnership, endpoint and Berlinger can provide Sponsors with a fully integrated solution, taking a 25-day manual temperature-monitoring data evaluation and turning it into instant decision making. This drastically reduces costs up to 7-digit figures and improves patient safety, allowing for fast decision-making through complete visibility of the temperature history. Sponsors and sites will reap immediate benefits through this sophisticated technology integration in a variety of areas:
“Patient safety has always been a high priority for endpoint. As cold chain logistics become increasingly important due to the ever-growing number of studies that work with biologics, we understand how vital it is to maintain the chain of custody. This ensures that IMP does not go outside of agreed temperature ranges for that product. We are happy to be partnering with Berlinger on an integration providing a seamless solution for both the sponsor and site,” says Jeff Rubesin, Senior Director, Product Strategy at endpoint Clinical. About endpoint About Berlinger Established in 1865 as a weaving manufacturer, Berlinger has developed its business over the years and has become a world-leading manufacturer of Doping Control Equipment and is among the top three leaders in the market of temperature monitoring solutions. Visit https://www.berlinger.com/usa/ to learn more. Contacts: Barbara Hoefelmayr
SOURCE endpoint Clinical |
View original content to download multimedia:
